These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28473136)

  • 61. Ranolazine reduces angina frequency and severity and improves quality of life: Observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR).
    Alexopoulos D; Kochiadakis G; Afthonidis D; Barbetseas J; Kelembekoglou P; Limberi S; Spanos A; Triantafyllidis G
    Int J Cardiol; 2016 Feb; 205():111-116. PubMed ID: 26730841
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Coronary artery calcification as a new predictor of non-target lesion revascularization during the chronic phase after successful percutaneous coronary intervention.
    Honda Y; Toyama T; Miyaishi Y; Kan H; Kawaguchi R; Adachi H; Hoshizaki H; Oshima S
    Cardiovasc Interv Ther; 2014 Oct; 29(4):315-23. PubMed ID: 24906449
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin.
    Pettus J; McNabb B; Eckel RH; Skyler JS; Dhalla A; Guan S; Jochelson P; Belardinelli L; Henry RH
    Diabetes Obes Metab; 2016 May; 18(5):463-74. PubMed ID: 26749407
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Association between diabetes mellitus and angina after acute myocardial infarction: analysis of the TRIUMPH prospective cohort study.
    Arnold SV; Spertus JA; Lipska KJ; Tang F; Goyal A; McGuire DK; Cresci S; Maddox TM; Kosiborod M
    Eur J Prev Cardiol; 2015 Jun; 22(6):779-87. PubMed ID: 24740679
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Quality of Life Changes After Chronic Total Occlusion Angioplasty in Patients With Baseline Refractory Angina.
    Hirai T; Grantham JA; Sapontis J; Cohen DJ; Marso SP; Lombardi W; Karmpaliotis D; Moses J; Nicholson WJ; Pershad A; Wyman RM; Spaedy A; Cook S; Doshi P; Federici R; Nugent K; Gosch KL; Spertus JA; Salisbury AC
    Circ Cardiovasc Interv; 2019 Mar; 12(3):e007558. PubMed ID: 30871356
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ranolazine versus placebo in patients with ischemic cardiomyopathy and persistent chest pain or dyspnea despite optimal medical and revascularization therapy: randomized, double-blind crossover pilot study.
    Shammas NW; Shammas GA; Keyes K; Duske S; Kelly R; Jerin M
    Ther Clin Risk Manag; 2015; 11():469-74. PubMed ID: 25848292
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.
    Bairey Merz CN; Handberg EM; Shufelt CL; Mehta PK; Minissian MB; Wei J; Thomson LE; Berman DS; Shaw LJ; Petersen JW; Brown GH; Anderson RD; Shuster JJ; Cook-Wiens G; Rogatko A; Pepine CJ
    Eur Heart J; 2016 May; 37(19):1504-13. PubMed ID: 26614823
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prospective study of the impact of diabetes mellitus newly diagnosed by glycated hemoglobin on outcomes in patients undergoing percutaneous coronary intervention.
    Tailakh MA; Friger M; Zahger D; Sidi A; Mazor-Dray E; Novack V
    Eur J Intern Med; 2017 Jan; 37():69-74. PubMed ID: 27665509
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ranolazine for the management of coronary artery disease.
    Cheng JW
    Clin Ther; 2006 Dec; 28(12):1996-2007. PubMed ID: 17296457
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of ranolazine on glycaemia in adults with and without diabetes: a meta-analysis of randomised controlled trials.
    Teoh IH; Banerjee M
    Open Heart; 2018; 5(2):e000706. PubMed ID: 30613407
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Angina Severity, Depression, and Response to Percutaneous Revascularization in Patients With Chronic Total Occlusion of Coronary Arteries.
    Bruckel JT; Jaffer FA; O'Brien C; Stone L; Pomerantsev E; Yeh RW
    J Invasive Cardiol; 2016 Feb; 28(2):44-51. PubMed ID: 26477043
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Medical therapy after successful percutaneous coronary revascularization.
    Hasdai D; Lerman A; Grill DE; Rihal CS; Holmes DR
    Ann Intern Med; 1999 Jan; 130(2):108-15. PubMed ID: 10068356
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
    Chaitman BR
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ranolazine for Refractory Angina in a Heart Transplant Recipient With Cardiac Allograft Vasculopathy.
    Yeung DF; Toma M; Davis MK; Ignaszewski A
    Am J Transplant; 2017 May; 17(5):1427-1428. PubMed ID: 28035732
    [No Abstract]   [Full Text] [Related]  

  • 75. Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina.
    Banerjee K; Ghosh RK; Kamatam S; Banerjee A; Gupta A
    Int J Cardiol; 2017 Jan; 227():556-564. PubMed ID: 27838121
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study.
    Kourlaba G; Vlachopoulos C; Parissis J; Kanakakis J; Gourzoulidis G; Maniadakis N
    BMC Health Serv Res; 2015 Dec; 15():566. PubMed ID: 26684327
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Spotlight on ranolazine in chronic stable angina pectoris.
    Siddiqui MA; Keam SJ
    Am J Cardiovasc Drugs; 2006; 6(5):357-9. PubMed ID: 17083271
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Improvement of Subjective Well-Being by Ranolazine in Patients with Chronic Angina and Known Myocardial Ischemia (IMWELL Study).
    Bavry AA; Park KE; Choi CY; Mahmoud AN; Wen X; Elgendy IY
    Cardiol Ther; 2017 Jun; 6(1):81-88. PubMed ID: 28044265
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Microvascular ischemia in patients with successful percutaneous coronary intervention: effects of ranolazine and isosorbide-5-mononitrate.
    Golino M; Spera FR; Manfredonia L; De Vita A; Di Franco A; Lamendola P; Villano A; Melita V; Mencarelli E; Lanza GA; Crea F
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6545-6550. PubMed ID: 30338825
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Coronary artery disease: a dam in the river for ranolazine.
    Head SJ; Kappetein AP
    Lancet; 2016 Jan; 387(10014):100-2. PubMed ID: 26474812
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.